Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13805964 | 0.86 | SMN1; SMN2 (0.43) | KMT2ASMN1; SMN2L3MBTL1KDM4EHTT | |
| SCHEMBL13805751 | 0.82 | HCAR3 (0.51) | HCAR3KMT2ASMN1; SMN2CDC25BL3MBTL1 | |
| SCHEMBL3946683 | 0.81 | GSTO1 (0.47) | HCAR3KMT2ASMN1; SMN2POLBPKM | |
| SCHEMBL3952406 | 0.81 | PKM (0.43) | HCAR3KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL3946930 | 0.81 | HCAR3 (0.50) | HCAR3KMT2ASMN1; SMN2CDC25BL3MBTL1 | |
| SCHEMBL22499489 | 0.79 | HCAR3 (0.55) | HCAR3KMT2ASMN1; SMN2L3MBTL1POLB | |
| SCHEMBL22499544 | 0.79 | KMT2A (0.41) | HCAR3KMT2ASMN1; SMN2AKR1B1L3MBTL1 | |
| SCHEMBL25300507 | 0.79 | MCL1 (0.51) | KMT2ASMN1; SMN2AKR1B1CDC25BL3MBTL1 | |
| SCHEMBL31401177 | 0.79 | APEX1 (0.61) | KMT2ASMN1; SMN2L3MBTL1POLBNSD2 | |
| SCHEMBL29452139 | 0.79 | APEX1 (0.61) | KMT2ASMN1; SMN2L3MBTL1POLBNSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544676-B2 | Sulfamoyl benzamides and methods of their use | ADOLOR CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CALIXA THERAPEUTICS, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007058960-A1 | SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS | ADOLOR CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058302-A1 | Sulfamoyl Benzamides and Methods of Their Use | CNR2, TRPV1, CNR1 | HCAR3 376/4885KMT2A 683/4885SMN1; SMN2 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.